What it is
TB-500 is the name commonly used for a thymosin beta-4–derived research peptide.
Evidence boundary
Investigational with limited human evidence. Treat this as research rather than as standard therapy.
Trial evidence
- PMID 41476424 — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
- PMID 42021992 — Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- PMID 42578445 — Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 500 mcg | 10 U (0.1 mL) | Once daily | 3.5 mg/week |
| Weeks 3–4 | 600 mcg | 12 U (0.12 mL) | Once daily | 4.2 mg/week |
| Weeks 5–8 | 750 mcg | 15 U (0.15 mL) | Once daily | 5.25 mg/week |
| Weeks 9–12 (target) | 1 mg | 20 U (0.2 mL) | Once daily | 7 mg/week |
Weeks 1–2 (titration)
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weeks 3–4
- Dose
- 600 mcg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- Once daily
- Weekly total
- 4.2 mg/week
Weeks 5–8
- Dose
- 750 mcg
- Draw / measure
- 15 U (0.15 mL)
- Frequency
- Once daily
- Weekly total
- 5.25 mg/week
Weeks 9–12 (target)
- Dose
- 1 mg
- Draw / measure
- 20 U (0.2 mL)
- Frequency
- Once daily
- Weekly total
- 7 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Daily titration approach (subcutaneous):
-
Weeks 1–2: 500 mcg/day (10 units at 5 mg/mL).
-
Weeks 3–4: 600 mcg/day.
-
Weeks 5–8: 750 mcg/day.
-
Weeks 9–12 (target): 1000 mcg (1 mg) /day.
-
Weekly total: ~3.5–7 mg/week (averages 5 mg/week across the cycle).
-
Timing: Once per day at a consistent time; rotate injection sites.
-
Local injection tolerance
Practical rules
- Keep expectations modest.
- Pair any recovery protocol with physical therapy, protein, and load management.
- Rotate sites.